Bizengri A Breakthrough Targeted Therapy For NRG1 Fusion-Positive Cancers
Bizengri represents a paradigm shift in treating NRG1+ cancers, offering hope for patients with historically poor prognoses.…
News
FDA Approves Kisunla: A New Hope In Early Alzheimer’s Treatment
April 18, 2025 — Phoenix, AZ — In a significant advancement for Alzheimer’s disease treatment,…
Checkpoint Therapeutics Achieves Milestone With Unloxcyt™ Approval For Advanced Skin Cancer
In a significant advancement for oncology therapeutics, the U.S. Food and Drug Administration (FDA) approved…
Eton Pharmaceuticals Expands Pediatric Endocrinology Portfolio With Increlex Acquisition
Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a leader in rare disease therapeutics, has announced a strategic…
Jemperli Gets FDA Approval To Take Its Place In Cancer Therapy
GlaxoSmithKline’s immunotherapy drug, Jemperli (dostarlimab-gxly), is making significant strides in oncology, particularly in treating endometrial…
Kineret (Anakinra) For The Treatment Of COVID-19-Associated Pneumonia Expands Its Immunomodulatory Applications
The U.S. Food and Drug Administration (FDA) has expanded its approval of Sobi’s (Swedish Orphan…
Oral Lupus Nephritis Drug Lupkynis (Voclosporin) Changing The Treatment Landscape
April 17, 2025 — Lupus nephritis (LN) is a serious autoimmune disease that has long…
Braftovi Combo Shows Promising Survival Benefits In BRAF-Mutant Colorectal Cancer
In a significant advancement for metastatic colorectal cancer (mCRC) patients with BRAF V600E mutations, Pfizer’s…
Ensartinib Shows Strong Efficacy in ALK-Positive Non-Small Cell Lung Cancer
Highlighted by Hong Kong DengYue Medicine What is Ensacove Ensartinib? Ensacove Ensartinib (X-396) is an…
Phase 3 Trial Of Crenessity (Crinecerfont) In Pediatric Congenital Adrenal Hyperplasia
The U.S. Food and Drug Administration (FDA) has approved Crenessity™ (crinecerfont) as an adjunctive treatment…
Copyright@ 2016-2024 Hong Kong Deng Yue Med Al Rights